Valuation: Dermata Therapeutics, Inc.

Market Cap 2.5M 2.27M 2.1M 1.89M 3.58M 235M 3.7M 25.22M 9.99M 126M 9.38M 9.18M 399M P/E 2026 *
-0.29x
P/E 2027 * -0.43x
Enterprise Value 2.5M 2.27M 2.1M 1.89M 3.58M 235M 3.7M 25.22M 9.99M 126M 9.38M 9.18M 399M EV / Sales 2026 *
25x
EV / Sales 2027 * 3.33x
Free-Float
77.68%
Yield 2026 *
-
Yield 2027 * -
1 day-3.65%
1 week-21.66%
Current month-22.77%
1 month-34.23%
3 months-59.01%
6 months-49.71%
Current year-74.20%
1 week 0.57
Extreme 0.566
0.78
1 month 0.57
Extreme 0.566
0.97
Current year 0.57
Extreme 0.566
4.66
1 year 0.57
Extreme 0.566
4.66
3 years 0.57
Extreme 0.566
133.5
5 years 0.57
Extreme 0.566
11,933.27
10 years 0.57
Extreme 0.566
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 07/12/2014
Director of Finance/CFO 48 31/08/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 31/03/2021
Director/Board Member 77 07/12/2014
Director/Board Member 78 19/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
16/08/26 Free

Chief Financial Officer

306,120 10.7966%
17/02/26 Buy

General Counsel

1,000 0.0353%
02/01/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
-3.65%-21.66%-80.50%-99.39% 2.5M
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+7.58%+12.54%+93.05% 60.62B
+0.63%+1.03%+23.11%+90.78% 55.5B
-1.26%+1.06%+12.43%+109.27% 47.58B
-0.15%-2.61%+20.00%+28.62% 43.69B
-3.15%-13.22%+146.30%+681.96% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%+0.06%+80.65%+59.68% 32.22B
+1.42%+7.41%-36.40%+393.49% 26.58B
Average -0.50%-1.57%+24.50%+147.12% 41B
Weighted average by Cap. -0.29%+0.33%+35.88%+150.13%

Financials

2026 *2027 *
Net sales 100K 90.85K 83.94K 75.82K 143K 9.39M 148K 1.01M 400K 5.04M 375K 367K 15.96M 750K 681K 630K 569K 1.07M 70.42M 1.11M 7.57M 3M 37.79M 2.81M 2.75M 120M
Net income -11.08M -10.07M -9.3M -8.4M -15.86M -1.04B -16.42M -112M -44.33M -558M -41.59M -40.71M -1.77B -13.78M -12.52M -11.57M -10.45M -19.72M -1.29B -20.42M -139M -55.13M -695M -51.72M -50.62M -2.2B
Net Debt - -
Projected Income Statement - Annual - Dermata Therapeutics, Inc.
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
16/11/26 US$0.5985 -3.65% 48,403
13/11/26 US$0.6212 -6.01% 160,686
12/11/26 US$0.6609 -7.57% 15,508
11/11/26 US$0.7150 +0.07% 82,770
10/11/26 US$0.7145 -7.21% 45,213
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6212USD
Average target price
4.000USD
Spread / Average Target
+543.92%
  1. Stock Market
  2. Stocks
  3. DRMA Stock